Clinical Study Results, Upcoming Events, and Financial Updates - Analyst Notes on Amgen, Insys, Alnylam, Seattle Genetics and Emergent BioSolutions

NEW YORK, May 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Amgen, Inc. (NASDAQ: AMGN), Insys Therapeutics, Inc. (NASDAQ: INSY), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Seattle Genetics, Inc. (NASDAQ: SGEN) and Emergent BioSolutions Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2424-100free.

--
Amgen, Inc. Analyst Notes
On May 9, 2014, Amgen, Inc. (Amgen) and AstraZeneca announced positive results from their Phase 3 AMAGINE-1 study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis. The Companies informed that the study has met all primary and secondary endpoints for both evaluated doses. "Data from the AMAGINE-1 study suggest that brodalumab may offer a new level of efficacy for patients with moderate-to-severe plaque psoriasis, a disease that affects more than 100 million people globally," said Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen. "This is the first read-out from our Phase 3 psoriasis clinical program and we look forward to obtaining additional Phase 3 data from our two head-to-head studies versus ustekinumab later this year." The full analyst notes on Amgen are available to download free of charge at:

http://www.analystsreview.com/2424-AMGN-14May2014.pdf

--
Insys Therapeutics, Inc. Analyst Notes
On May 7, 2014, Insys Therapeutics, Inc. (Insys) announced that it will be presenting at the 2014 UBS Global Healthcare Conference to be held on May 19-21, 2014 at the Sheraton New York Times Square Hotel in New York City. The Company's President and CEO, Michael L. Babich, and CFO, Darryl Baker, are scheduled to present on May 20, 2014 at 2:30 p.m. EDT. The full analyst notes on Insys are available to download free of charge at:

http://www.analystsreview.com/2424-INSY-14May2014.pdf

--
Alnylam Pharmaceuticals, Inc. Analyst Notes
On May 8, 2014, Alnylam Pharmaceuticals, Inc. (Alnylam) reported its Q1 2014 financial results. During the quarter, the Company reported revenues of $8.3 million, down 55.6% YoY due to the recognition of the remaining deferred revenue under the Cubist agreement of $9.7 million resulting from the termination of the said agreement in February 2013, as well as the end of Alnylam's performance obligations thereunder. Q1 2014 net loss was $250.9 million, or $3.70 loss per share, compared to a net loss of $9.0 million, or $0.15 loss per share, in Q1 2013. "Alnylam's balance sheet has never been stronger, and we have ended the first quarter with just over $1 billion in cash," said Michael Mason, Vice President of Finance and Treasurer of Alnylam. "As for financial guidance this calendar year, we expect to end 2014 with greater than $825 million in cash. We believe that this balance sheet allows us to invest in a broad pipeline of genetic medicines and to maintain financial independence through to multiple product launches." The full analyst notes on Alnylam are available to download free of charge at:

http://www.analystsreview.com/2424-ALNY-14May2014.pdf

--
Seattle Genetics, Inc. Analyst Notes
On May 7, 2014, Seattle Genetics, Inc. (Seattle Genetics) announced that it will be presenting at the UBS Global Healthcare Conference. The presentation will be webcast live will be on Wednesday, May 20, 2014 at 1:00 p.m. ET in New York. The full analyst notes on Seattle Genetics are available to download free of charge at:

http://www.analystsreview.com/2424-SGEN-14May2014.pdf

--
Emergent BioSolutions Inc. Analyst Notes
On May 8, 2014, Emergent BioSolutions Inc. (Emergent BioSolutions) reported its Q1 2014 financial results. During the quarter, the Company's revenue totaled $53.9 million, up 25% YoY. Q1 2014 net loss came in at $20.2 million, or $0.55 loss per share, compared to a net loss of $8.1 million, or $0.22 loss per share, in Q1 2013. "Our first quarter financial performance met expectations, with our reported revenue being at the upper end of our guidance. Operationally, we initiated manufacturing of BioThrax consistency lots in Building 55 after finalizing comparability protocols with FDA. Further, we completed the initial phase of the Cangene integration and are preparing for the potential launch of IXinity, a proprietary recombinant coagulation Factor IX product candidate included in the Cangene acquisition," said Daniel J. Abdun-Nabi, President and CEO of Emergent BioSolutions. For full-year 2014, the Company reaffirmed its revenue expectation of $415.0 million to $445.0 million, and net income of $30.0 million to $40.0 million; while for Q2 2014, it expects revenues between $95 and $110 million. The full analyst notes on Emergent BioSolutions are available to download free of charge at:

http://www.analystsreview.com/2424-EBS-14May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED